In this issue:
Fatigue ubiquitous in PsA but rarely acknowledged by physicians
BE AGILE 2 demonstrates longterm safety and efficacy of bimekizumab for AS
BE ACTIVE 2: bimekizumab efficacy sustained long-term in PsA
Physical functioning is a key driver of QoL
Polypharmacy linked with poorer QoL
Shortened life expectancy in patients with RA and axSpA
The impact of a csDMARD + TNF inhibition in axSpA
Ixekizumab efficacious for AS irrespective of baseline inflammation
Patients' perspectives on shared pharmacologic decision-making
Pharmacokinetic boosting may allow once-daily reduced dose tofacitinib
Please login below to download this issue (PDF)